Data confirms that semaglutide lowers blood pressure
US scientists have released new data supporting initial findings that diabetes and weight loss drug semaglutide (Wegovy/Ozempic) lowers cardiovascular risk regardless of blood sugar. A weekly dose of semaglutide 2.4mg significantly reduced the risk of major adverse cardiovascular events (MACEs) in people with overweight… Read More